Sophia Genetics
EPFL Innovation Park
Batiment D
Lausanne
CH-1015
Tel: 41-21-693-90-44
Website: http://www.sophiagenetics.com/
Email: info@sophiagenetics.com
56 articles with Sophia Genetics
-
SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022
6/6/2022
SOPHiA GENETICS (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, provides an update on its multimodal DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
SOPHiA GENETICS Announces Three Poster Presentations and One Online Publication Accepted at the 2022 American Society of Clinical Oncology Annual (ASCO) Meeting
6/1/2022
SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced three abstracts accepted for poster presentation and one for online publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago.
-
SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022 Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed
5/10/2022
SOPHiA GENETICS SA, a leader in data-driven medicine, reported financial results for the first quarter ended March 31, 2022.
-
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2022 on May 10, 2022
4/13/2022
SOPHiA GENETICS SA today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022.
-
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
SOPHiA GENETICS to Participate in Fireside Chat at Barclays Global Healthcare Conference
3/4/2022
SOPHiA GENETICS SA announced Chief Executive Officer and Co-Founder Dr. Jurgi Camblong will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16 at 11:15 a.m. ET/5:15 p.m. CET at the Loews Miami Beach Hotel in Miami, FL, United States.
-
SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
2/16/2022
SOPHiA GENETICS SA today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022.
-
Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICS
2/1/2022
SOPHiA GENETICS have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes, one of the 18 French Cancer Comprehensive Centers, to further support the implementation, automatization, and accreditation of solid tumor tests, to include lung, breast, ovarian and onco-hematological cancers.
-
SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/29/2021
SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Officer Ross Muken, will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
-
SOPHiA GENETICS Reports Third Quarter 2021 Financial Results and Raises 2021 Guidance
11/10/2021
SOPHiA GENETICS SA, reported financial results for the third quarter ended September 30, 2021.
-
SOPHiA GENETICS to Participate in Upcoming November 2021 Investor Conferences
10/28/2021
SOPHiA GENETICS SA announced the company will be participating virtually in the following investor conferences.
-
SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases
10/12/2021
SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced the launch of SOPHiA Clinical Exome Solution v3, a new genomic application that offers enhanced probe design and increased detection capabilities for a deeper investigation of Mendelian diseases.
-
Here’s a look at a few of the industry expansions that have been announced so far this month.
-
Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.
-
SOPHiA GENETICS Reports Second Quarter 2021 Financial Results and Issues 2021 Guidance
9/9/2021
SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021.
-
DA32 Life Science SPAC Prices $200M IPO
7/28/2021
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO). -
SOPHiA GENETICS Announces Closing of $234 Million Initial Public Offering and $20 Million Private Placement
7/27/2021
SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced the closing of its initial public offering of 13,000,000 ordinary shares at a price of $18 per share.
-
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
-
Money on the Move: June 30 – July 6
7/7/2021
The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. -
GE Healthcare and SOPHiA GENETICS to collaborate to match treatments to multimodal patient data and cancer type
7/6/2021
GE Healthcare and SOPHiA GENETICS announced that they have signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each patient's genomic profile and cancer type, helping to ensure the most effective and personalized treatment.